HeartSciences (HSCSW) Debt to Equity (2022 - 2026)

HeartSciences has reported Debt to Equity for 4 years, with the latest figure at $0.16 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to $0.16; the trailing twelve-month figure through Jan 2026 stood at $0.16 (changed N/A YoY), and the FY2023 full-year result was $2.17, up 395.67% from the prior year.
• Debt to Equity for Q1 2026 stood at $0.16, up from $0.01 in the prior quarter.
• The five-year high for Debt to Equity was $2.17 in Q2 2023, with the low at -$3.88 in Q1 2023.
• Historically, Debt to Equity has averaged -$0.35 across 4 years, with a median of $0.05 in 2024.
• The largest YoY upside for Debt to Equity was 395.67% in 2023 against a maximum downside of 377.78% in 2023.
• HeartSciences' Debt to Equity stood at $0.35 in 2022, then tumbled by 377.78% to -$0.96 in 2023, then surged by 101.28% to $0.01 in 2024, then soared by 1190.62% to $0.16 in 2026.
• The last three Debt to Equity figures came in at $0.16 (Q1 2026), $0.01 (Q4 2024), and $0.08 (Q3 2024), per Business Quant data.